Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475A in Japanese participants with advanced cSCC
NCT06041802Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of berahyaluronidase alfa + pembrolizumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Merck & Co.. Started Oct 2023; status: active, not recruiting.
02
Drugs
berahyaluronidase alfa + pembrolizumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06041802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041802.